CL2011001391A1 - Formas solidas cristalinas del acido (s)-4-((2s,3s)-7-carbamoil-1,1-dietil-3-metoxi-1,2,3,4-tetrahidronaftalen-2-ilamino)-2-ciclohexilmetil-butirico y de la sal clorhidrato; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para mejorar la movilidad del tracto gastrointestinal. - Google Patents
Formas solidas cristalinas del acido (s)-4-((2s,3s)-7-carbamoil-1,1-dietil-3-metoxi-1,2,3,4-tetrahidronaftalen-2-ilamino)-2-ciclohexilmetil-butirico y de la sal clorhidrato; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para mejorar la movilidad del tracto gastrointestinal.Info
- Publication number
- CL2011001391A1 CL2011001391A1 CL2011001391A CL2011001391A CL2011001391A1 CL 2011001391 A1 CL2011001391 A1 CL 2011001391A1 CL 2011001391 A CL2011001391 A CL 2011001391A CL 2011001391 A CL2011001391 A CL 2011001391A CL 2011001391 A1 CL2011001391 A1 CL 2011001391A1
- Authority
- CL
- Chile
- Prior art keywords
- formula
- acid
- crystalline forms
- tetrahydronaphthalen
- cyclohexylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
FORMAS CRISTALINAS I Y 11 DEL ÁCIDO (S: -4-":25, 35)- 7 -CARBAMOLL-1 .1-( -ETIL-3-METOXI-1 ,2,3.4 -TETRAHIDRONAFTALEN-2 ILAMINO)-2 CICLOHEXILMETIL BUTIRICO. DE FORMULA I. CARACTERIZADAS POR VALORES 2E DEL ESPECTRO DE DIFRACCIÓN DE RAYOS X CADA UNA, ADEMÁS DE LA FORMA SÓLIDA CRISTALINA DE LA SAL CLORTL DRATO DEL MISMO CON SUS RESPECTIVOS VALORES 2E DEL ESPECTRO DE DIFRACCIÓN DE RAYOS X. PROCESO DE SÍNTESIS DEL COMPUESTO DE FORMULA IA PARTIR DEL COMPUESTO INTERMEDIARIO DE FÓRMULA 4, EL CUAL PRESENTA UN PRECURSOR DE FÓRMULA 5. EN COMBINACIÓN CON UN COMPUESTO DE FÓRMULA 3 PARA FORMAR Y REIVINDICAR UN COMPUESTO DE FÓRMULA 2 O SU SAL CLORHIDRATO. CAMPOSICION FARMACÉUTICA QUE COMPRENDE LAS FORMAS SÓLIDAS CRISTALINAS DEL ÁCIDO ($)-4(( 28.38)-7-CA RBAMOIL- 1,1•DIETIL-3-METOXI•1.2. 3, 4-TETRAHIDROBAFTALER-ILAMI)-22•CICLOHEXILMETIL-BULIRICO. Y USO DE LA FORMA SÓLIDA CRISTALINA DEL MISMO PARA EL TRATAMIENTO DE LA DISFUNCLÓN INTESTINAL INDUCIDA POR AGENTES OPIOLDES O ILEO POSOPERATORIO. DEL TRASTORNO DE MOVILIDAD REDUCIDA DEL TRACTO INTESTINAL Y PARA ANTAGONIZAR UN RECEPTOR OPIOLDE U EN UN MAMÍFERO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12125408P | 2008-12-10 | 2008-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011001391A1 true CL2011001391A1 (es) | 2011-11-11 |
Family
ID=42122774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001391A CL2011001391A1 (es) | 2008-12-10 | 2011-06-08 | Formas solidas cristalinas del acido (s)-4-((2s,3s)-7-carbamoil-1,1-dietil-3-metoxi-1,2,3,4-tetrahidronaftalen-2-ilamino)-2-ciclohexilmetil-butirico y de la sal clorhidrato; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para mejorar la movilidad del tracto gastrointestinal. |
Country Status (21)
Country | Link |
---|---|
US (4) | US8101794B2 (es) |
EP (1) | EP2376427B1 (es) |
JP (1) | JP5650657B2 (es) |
KR (1) | KR101685187B1 (es) |
CN (1) | CN102245564B (es) |
AR (1) | AR074592A1 (es) |
AU (1) | AU2009324709B2 (es) |
BR (1) | BRPI0922920A2 (es) |
CA (1) | CA2745441C (es) |
CL (1) | CL2011001391A1 (es) |
CO (1) | CO6390054A2 (es) |
ES (1) | ES2645087T3 (es) |
IL (1) | IL213093A0 (es) |
MX (1) | MX2011006209A (es) |
MY (1) | MY179041A (es) |
NZ (1) | NZ593377A (es) |
RU (1) | RU2512390C2 (es) |
SG (1) | SG172016A1 (es) |
TW (1) | TWI449685B (es) |
WO (1) | WO2010068649A1 (es) |
ZA (1) | ZA201104319B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072336A1 (es) | 2007-12-11 | 2010-08-25 | Theravance Inc | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion |
EP2231589B1 (en) | 2007-12-11 | 2013-02-13 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
TW201118084A (en) * | 2009-09-18 | 2011-06-01 | Adolor Corp | The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders |
EP2760826A1 (en) * | 2011-09-30 | 2014-08-06 | Theravance, Inc. | Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498196B1 (en) | 1998-12-22 | 2002-12-24 | Edward Roberts | Compounds useful in pain management |
US6844368B1 (en) | 1998-12-22 | 2005-01-18 | Edward Roberts | Compounds useful in pain management |
US6231594B1 (en) | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
JP2005526137A (ja) * | 2002-05-17 | 2005-09-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノテトラリン−誘動尿素のバニロイドvr1受容体調節剤 |
MXPA05010821A (es) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
SE0301794D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use III |
EP2097083A2 (en) | 2006-11-07 | 2009-09-09 | Nektar Therapeutics AL, Corporation | Dosage forms and co-administration of an opioid agonist and an opioid antagonist |
EP1997493A1 (en) * | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
AR072336A1 (es) * | 2007-12-11 | 2010-08-25 | Theravance Inc | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion |
EP2231589B1 (en) | 2007-12-11 | 2013-02-13 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
-
2009
- 2009-12-09 ES ES09793383.2T patent/ES2645087T3/es active Active
- 2009-12-09 JP JP2011540855A patent/JP5650657B2/ja not_active Expired - Fee Related
- 2009-12-09 MX MX2011006209A patent/MX2011006209A/es active IP Right Grant
- 2009-12-09 TW TW098142108A patent/TWI449685B/zh not_active IP Right Cessation
- 2009-12-09 SG SG2011041605A patent/SG172016A1/en unknown
- 2009-12-09 CN CN200980149818.7A patent/CN102245564B/zh not_active Expired - Fee Related
- 2009-12-09 MY MYPI2011002349A patent/MY179041A/en unknown
- 2009-12-09 EP EP09793383.2A patent/EP2376427B1/en not_active Not-in-force
- 2009-12-09 BR BRPI0922920A patent/BRPI0922920A2/pt not_active IP Right Cessation
- 2009-12-09 AU AU2009324709A patent/AU2009324709B2/en not_active Ceased
- 2009-12-09 CA CA2745441A patent/CA2745441C/en active Active
- 2009-12-09 RU RU2011128393/04A patent/RU2512390C2/ru active
- 2009-12-09 WO PCT/US2009/067271 patent/WO2010068649A1/en active Application Filing
- 2009-12-09 US US12/633,944 patent/US8101794B2/en not_active Expired - Fee Related
- 2009-12-09 NZ NZ593377A patent/NZ593377A/xx not_active IP Right Cessation
- 2009-12-09 KR KR1020117015637A patent/KR101685187B1/ko active IP Right Grant
- 2009-12-10 AR ARP090104803A patent/AR074592A1/es unknown
-
2011
- 2011-05-24 IL IL213093A patent/IL213093A0/en active IP Right Grant
- 2011-06-08 CL CL2011001391A patent/CL2011001391A1/es unknown
- 2011-06-08 CO CO11070977A patent/CO6390054A2/es active IP Right Grant
- 2011-06-09 ZA ZA2011/04319A patent/ZA201104319B/en unknown
- 2011-12-19 US US13/330,358 patent/US8324236B2/en active Active
-
2012
- 2012-10-29 US US13/663,083 patent/US8486958B2/en active Active
-
2013
- 2013-06-17 US US13/919,260 patent/US8969367B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009009492A (es) | Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas. | |
AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
EA201170922A1 (ru) | Производные сульфонамида | |
CL2007002607A1 (es) | Compuestos derivados de aril-sulfonamida o piridin-sulfonamida; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o trastorno mediado por las interacciones de los linfocitos, tales como artritis reumatoide, | |
EA200900877A1 (ru) | Пиперидиновые агонисты gpcr | |
EA201290416A1 (ru) | Новые спиропиперидиновые соединения | |
CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
CL2007003487A1 (es) | Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno, inhibidor del transportador de glucosa sodio-dependiente; proceso de preparacion; composicion farmaceutica, util para el tratamiento de dia | |
EA200900796A1 (ru) | Пиперидиновые агонисты gpcr | |
EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
EA201000046A1 (ru) | Замещенные имидазогетероциклы | |
EA200900880A1 (ru) | Пиперидиновые агонисты gpcr | |
CR20120177A (es) | Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes | |
BRPI0922566A2 (pt) | polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença. | |
UY31803A (es) | Compuesto cristalino | |
ATE520651T1 (de) | Substituierte phenylmethylbicyclocarbonsäureamidverbindungen | |
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
CL2011001391A1 (es) | Formas solidas cristalinas del acido (s)-4-((2s,3s)-7-carbamoil-1,1-dietil-3-metoxi-1,2,3,4-tetrahidronaftalen-2-ilamino)-2-ciclohexilmetil-butirico y de la sal clorhidrato; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para mejorar la movilidad del tracto gastrointestinal. | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
ECSP10010499A (es) | Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida | |
BR112012020557A2 (pt) | formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio. | |
EA201000439A1 (ru) | Бензотиазолы в качестве модуляторов рецептора грелина | |
CL2007000680A1 (es) | Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc. | |
CL2008000554A1 (es) | Compuestos derivados de diaminopirimidina sustituida; metodo de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario, un estado patologico doloroso, un trastorno res | |
BRPI0920251A2 (pt) | composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. |